Economic Atlas
Companies/Ensysce Biosciences, Inc.
Company profile

Ensysce Biosciences, Inc.

NASDAQ: ENSC · Healthcare · Biotechnology
PublicHQ La Jolla, CACIK 0001716947Reports USD
#707 of 1,418 Healthcare companies by revenue37th-percentile growth
EA Score
31D
Revenue TTM
$1.5M
Rev growth YoY (TTM)
-76.6%
Net income (FY)
-$10.2M
Employees
9
as of 2026-08-24
Market cap
$5.7M
as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$5.1M$5.1M2025
Net income-$10.2M-$10.2M2025
Operating income-$10.2M-$10.2M2025
Total assets$7.5M$7.5M2025
Liabilities$4.6M$4.6M2025
Equity$3.2M$3.2M2025

Revenue trend

FY2021 – FY2025 · USD
FY21
FY22
FY22
FY23
FY24
FY25

Revenue by segment

Filed disclosures · FY2025
By product
MPAR100%
By geography

Not disclosed.

The read

What is Ensysce Biosciences, Inc.’s revenue?

Ensysce Biosciences, Inc. booked $5.1M in FY2025 revenue, contracting 2.8% year over year — slower than 63% of Healthcare companies we track, at a -200.8% net margin.

Peers · Healthcare
Petros Pharmaceuticals, Inc.48DRegenerative Medical Technology Group Inc.36DWellbeing Digital Sciences Inc.——Banyan Corp.——Procyon Corporation——InMed Pharmaceuticals Inc.45D
Key facts
CEOD. Lynn Kirkpatrick
SectorHealthcare
IndustryBiotechnology
HeadquartersLa Jolla, CA
ExchangeNASDAQ: ENSC
Employees9
IPO date2018-03-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.